NetworkNewsBreaks – Genprex Inc. (NASDAQ: GNPX)
Post# of 231
(Total Views: 307)
Posted On: 09/02/2020 3:11:22 PM
NetworkNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Appoints New VP to Oversee Regulatory Affairs
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, has appointed William E. Gannon Jr., MD, MBA, as vice president of Regulatory Affairs. With more than three decades of experience in the biotech and pharmaceutical industries and an impressive background in oncology and gene therapy, Gannon brings invaluable expertise in the areas of clinical development, regulatory affairs and commercialization of products. He is currently chief scientific officer and medical director at Capital City Technical Consulting, where he has directed clinical trial development and operations management for clients in both the biotech and pharmaceutical industries. In his new role at Genprex, Gannon will oversee the company’s clinical trials, including those that combine Genprex’s lead drug candidate, GPX-001 for non-small cell lung cancer (“NSCLC”), with AstraZeneca’s targeted therapy Tagrisso(R) and with immunotherapy Keytruda(R). “We are pleased to have Dr. Gannon join our team,” said Genprex chairman and CEO Rodney Varner in the press release. “His extensive experience in the management of clinical trials, from designing trials to building operational teams, will be an important asset for us as we work toward initiating our upcoming trials and seeing them through to successful completion.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, has appointed William E. Gannon Jr., MD, MBA, as vice president of Regulatory Affairs. With more than three decades of experience in the biotech and pharmaceutical industries and an impressive background in oncology and gene therapy, Gannon brings invaluable expertise in the areas of clinical development, regulatory affairs and commercialization of products. He is currently chief scientific officer and medical director at Capital City Technical Consulting, where he has directed clinical trial development and operations management for clients in both the biotech and pharmaceutical industries. In his new role at Genprex, Gannon will oversee the company’s clinical trials, including those that combine Genprex’s lead drug candidate, GPX-001 for non-small cell lung cancer (“NSCLC”), with AstraZeneca’s targeted therapy Tagrisso(R) and with immunotherapy Keytruda(R). “We are pleased to have Dr. Gannon join our team,” said Genprex chairman and CEO Rodney Varner in the press release. “His extensive experience in the management of clinical trials, from designing trials to building operational teams, will be an important asset for us as we work toward initiating our upcoming trials and seeing them through to successful completion.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Genprex Inc. (GNPX) Stock Research Links
Scroll down for more posts ▼